New Drugs and Clinical Research · us
FDA Approves Lembaz to Reduce Mortality in Infantile-Onset Niemann-Pick Disease, With a Warning of Permanent Hearing Loss
An integrated analysis of 36 patients offers a treatment option to extend life in this rare genetic disease. But the limitations of externally controlled studies, repeated intrathecal injections, and hearing risks also shape how this approval should be understood.
For patients with Niemann-Pick disease type C (NPC) who begin losing mobility, coordination, and the ability to swallow early in childhood, whether treatment can provide more time to live is the most urgent question for families. On November 17, the U.S. Food and Drug Administration (FDA) approved Lembaz (adrabetadex), making it the first drug approved to reduce the risk of death in patients with infantile-onset NPC. This development also comes with a serious warning about permanent hearing loss.
The approval covers children and adults weighing at least 7 kilograms whose neurological symptoms began before age six. Eligibility therefore depends on when neurological symptoms began, rather than requiring patients to currently be under six. The FDA noted that two NPC therapies had previously been approved, but neither had been shown to reduce the risk of death.
NPC is an inherited lysosomal storage disease in which cells cannot properly process cholesterol and other lipids, with the accumulating substances gradually damaging neurological function. According to Beren Therapeutics, adrabetadex works by helping transport cholesterol within cells. Trained healthcare professionals must administer the drug every two weeks by intrathecal injection, directly into the spinal canal. Continued treatment also means families must make repeated trips to medical facilities capable of administering it.
The core evidence supporting approval was an integrated survival analysis of 36 treated patients from three clinical studies and one expanded access program. Compared with matched external control patients, the treatment group had a 55% lower risk of death, with median overall survival of 8.5 years, versus 4.9 years in the control group. Pharmacy Times reported that a survival benefit was observed regardless of concomitant miglustat use. However, the difference between group medians cannot be directly interpreted as the additional lifespan each patient can expect.
This survival comparison was not a randomized trial. Contemporary Pediatrics noted that even after matching, differences between treated patients and historical controls may not have been fully accounted for. The publication also cautioned that a previously reported 71% reduction in the risk of death came from an analysis of a different patient population and should not be used interchangeably with the 55% figure used for this approval.
Safety is another central consideration in treatment decisions. Lembaz carries a boxed warning for hearing impairment, including the risk of permanent deafness. Comprehensive, regular hearing assessments are required before and during treatment, and the results also inform dose adjustments. Contemporary Pediatrics also reported that ataxia and fatigue may occur after administration and have led to hospitalization. The potential benefit of longer survival must be weighed alongside these risks and the burden of long-term monitoring.
Beren expects to begin supplying the drug to treatment sites across the United States in early December. It has also launched family support and caregiver connection programs to help locate facilities and address insurance, transportation, and financial assistance for eligible individuals. For patients and their families, the approval makes extending life a treatment goal they can discuss. Sustained access to drug administration and hearing monitoring services is the next test of bringing this development into everyday care.